Genmab Affirms FY2026 Sales Guidance of $4.065B-$4.395B vs $4.300B Est

Benzinga Newsdesk www.benzinga.com Negative 69.5%

Neg 69.5% Neu 0% Pos 0%

Genmab (NASDAQ:GMAB) affirms FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.065 billion-$4.395 billion vs $4.300 billion estimate.